Cognitive and behavioral effects of quetiapine in Alzheimer disease patients

Alzheimer Dis Assoc Disord. 2002 Apr-Jun;16(2):128-30. doi: 10.1097/00002093-200204000-00011.


In a prospective, open-label, 12-week pilot study in outpatients with probable Alzheimer disease (AD) with psychosis or aggressive behaviors, we used the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Neuropsychiatric Inventory (NPI) to evaluate the cognitive and behavioral effects of quetiapine. After receiving doses ranging from 50 to 150 mg, patients given quetiapine showed a significant decrease of delusions, aggression, and overall behaviors based on NPI scores at 6 and 12 weeks. ADAS-cog scores did not show a significant change over 12 weeks. This study provides initial evidence that quetiapine does not significantly worsen cognition in AD outpatients.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Aggression
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / psychology
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / pharmacology*
  • Dibenzothiazepines / administration & dosage
  • Dibenzothiazepines / pharmacology*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Psychotic Disorders
  • Quetiapine Fumarate
  • Treatment Outcome


  • Antipsychotic Agents
  • Dibenzothiazepines
  • Quetiapine Fumarate